Clinical trial
The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder
NCT00438971 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00438971 |
|---|---|
| Title | The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder |
| Official title | The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Panic Disorder |
| Intervention type | Drug |
| Interventions | Duloxetine |
| Enrollment | 15 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Feb 22, 2007 |
| Last update posted | Apr 27, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: